Board of Directors

http://signssigns1.bcz.com/2018/08/31/bad-medical-school-personal-statement-examples/

Charles L. Bisgaier, Ph.D., Chairman

Charles L. Bisgaier, Ph.D., is currently the Co-founder and Chief Executive Manager of Michigan Life Ventures, LLC (MLV), a private company that funds and assists early stage companies primarily in Michigan.  He has been instrumental in securing funds for several start up companies in Michigan.

 MLV is the lead investor in Hygieia, a revenue stage company developing a novel medical device guiding diabetic patients to appropriate dosage when self-administering insulin to maintain glycemic control. The device, “d-NAV” has obtained its CE-registration, and is being test marketed in Northern Ireland. Dr. Bisgaier also served as interim President, CEO, and Director of ProNAi Therapeutics, Inc., (2010-2012), a gene-silencing platform technology company.   His initial leadership resulted in hiring a CEO and the company raised $59.5 M and went public (formerly DNAi) in 2014.  Dr. Bisgaier is the Co-founder, Chairman and Chief Scientific Officer of Gemphire Therapeutics.   Gemphire has in-licensed a late stage lipid-regulating clinical candidate, gemcabene, which was developed and co-invented by Dr. Bisgaier while at Parke-Davis/Warner-Lambert and further developed by Pfizer Inc.  Gemphire (GEMP) went public in 2016.

Dr. Bisgaier Co-founded the first Esperion Therapeutics (ESPR-1998-2004) where he was a Company Director and the Vice-President of Pharmacology until 2004 when the company was acquired by Pfizer. Dr. Bisgaier was the Senior Director of Pharmacology (2004-2006) at the Esperion Division of Pfizer Global Research and Development. Dr. Bisgaier was formerly an Associate Research Fellow in the Department of Vascular and Cardiac Disease at Parke-Davis (1990-1998). There he participated in the discovery and development of cholesteryl ester transfer protein (CETP) inhibitors, gemfibrozil (LOPID®), atorvastatin (LIPITOR®), and CI-1027 (GEMCABENE).

Dr. Bisgaier received a B.A. (1974) in Biology from the State University College at Oneonta, NY, and a M.S. (1977) and Ph.D. (1981) in biochemistry from George Washington University. Dr. Bisgaier currently is an Adjunct Associate Professor of Pharmacology at the University of Michigan. He serves on the board of both non-profit organizations and private companies. He is a named inventor on many patents and patent applications, and has published over 80 peer reviewed manuscripts and reviews.

Nalini Ghag-Motwani, Ph.D.

Dr. Motwani has over 25 years of experience in research and management in the field of biotechnology including recombinant protein production. Dr. Motwani is co-inventor of 5 patents on yeast expression system for recombinant proteins.  Prior to founding BioSavita, Dr. Motwani was one of the founding scientists of Strohtech/Apex Bioscience, which was involved in the development of a cost-effective yeast expression system to produce genetically engineered hemoglobins. Dr. Motwani negotiated an arrangement with Apex to start BioSavita. She has been successful in securing NIH-SBIR and state grants, private funds, and licenses for BioSavita. Under her leadership, the BioSavita scientific team developed a proprietary twin cassette expression system for cost-effective production of recombinant proteins including heterodimer of cytokines and monoclonal antibodies in yeast. She was a licensing consultant for the technology transfer office at the University of Michigan and a visiting scientist at the Karolinska Institute in Sweden. She received her Masters degree from Haffkine Institute in Bombay and her Ph.D. from Wayne State University in Michigan.

our website